These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. Tee AR; Blenis J; Proud CG FEBS Lett; 2005 Aug; 579(21):4763-8. PubMed ID: 16098514 [TBL] [Abstract][Full Text] [Related]
23. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919 [TBL] [Abstract][Full Text] [Related]
24. Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity. Sato T; Akasu H; Shimono W; Matsu C; Fujiwara Y; Shibagaki Y; Heard JJ; Tamanoi F; Hattori S J Biol Chem; 2015 Jan; 290(2):1096-105. PubMed ID: 25422319 [TBL] [Abstract][Full Text] [Related]
25. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. Makovski V; Haklai R; Kloog Y Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191 [TBL] [Abstract][Full Text] [Related]
26. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678 [TBL] [Abstract][Full Text] [Related]
27. Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling. Wang X; Fonseca BD; Tang H; Liu R; Elia A; Clemens MJ; Bommer UA; Proud CG J Biol Chem; 2008 Nov; 283(45):30482-92. PubMed ID: 18676370 [TBL] [Abstract][Full Text] [Related]
28. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. Castro AF; Rebhun JF; Clark GJ; Quilliam LA J Biol Chem; 2003 Aug; 278(35):32493-6. PubMed ID: 12842888 [TBL] [Abstract][Full Text] [Related]
29. Rheb binds and regulates the mTOR kinase. Long X; Lin Y; Ortiz-Vega S; Yonezawa K; Avruch J Curr Biol; 2005 Apr; 15(8):702-13. PubMed ID: 15854902 [TBL] [Abstract][Full Text] [Related]
30. Rheb activation disrupts spine synapse formation through accumulation of syntenin in tuberous sclerosis complex. Sugiura H; Yasuda S; Katsurabayashi S; Kawano H; Endo K; Takasaki K; Iwasaki K; Ichikawa M; Kobayashi T; Hino O; Yamagata K Nat Commun; 2015 Apr; 6():6842. PubMed ID: 25880340 [TBL] [Abstract][Full Text] [Related]
31. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis. Lacher MD; Pincheira R; Zhu Z; Camoretti-Mercado B; Matli M; Warren RS; Castro AF Oncogene; 2010 Dec; 29(50):6543-56. PubMed ID: 20818424 [TBL] [Abstract][Full Text] [Related]
32. Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb. Lee MN; Ha SH; Kim J; Koh A; Lee CS; Kim JH; Jeon H; Kim DH; Suh PG; Ryu SH Mol Cell Biol; 2009 Jul; 29(14):3991-4001. PubMed ID: 19451232 [TBL] [Abstract][Full Text] [Related]
33. Structural basis for the unique biological function of small GTPase RHEB. Yu Y; Li S; Xu X; Li Y; Guan K; Arnold E; Ding J J Biol Chem; 2005 Apr; 280(17):17093-100. PubMed ID: 15728574 [TBL] [Abstract][Full Text] [Related]
34. Rheb GTPase controls apoptosis by regulating interaction of FKBP38 with Bcl-2 and Bcl-XL. Ma D; Bai X; Zou H; Lai Y; Jiang Y J Biol Chem; 2010 Mar; 285(12):8621-7. PubMed ID: 20048149 [TBL] [Abstract][Full Text] [Related]
35. Tuberous sclerosis complex: from Drosophila to human disease. Pan D; Dong J; Zhang Y; Gao X Trends Cell Biol; 2004 Feb; 14(2):78-85. PubMed ID: 15102439 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth. Wang Y; Hong X; Wang J; Yin Y; Zhang Y; Zhou Y; Piao HL; Liang Z; Zhang L; Li G; Xu G; Kwiatkowski DJ; Liu Y Oncogene; 2017 Feb; 36(6):756-765. PubMed ID: 27399332 [TBL] [Abstract][Full Text] [Related]
37. REDD2 is enriched in skeletal muscle and inhibits mTOR signaling in response to leucine and stretch. Miyazaki M; Esser KA Am J Physiol Cell Physiol; 2009 Mar; 296(3):C583-92. PubMed ID: 19129461 [TBL] [Abstract][Full Text] [Related]
38. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Uhlmann EJ; Li W; Scheidenhelm DK; Gau CL; Tamanoi F; Gutmann DH Glia; 2004 Aug; 47(2):180-8. PubMed ID: 15185396 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of retrograde transport modulates misfolded protein accumulation and clearance in motoneuron diseases. Cristofani R; Crippa V; Rusmini P; Cicardi ME; Meroni M; Licata NV; Sala G; Giorgetti E; Grunseich C; Galbiati M; Piccolella M; Messi E; Ferrarese C; Carra S; Poletti A Autophagy; 2017 Aug; 13(8):1280-1303. PubMed ID: 28402699 [TBL] [Abstract][Full Text] [Related]
40. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway. Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]